Join us at the EHDN 2021 Remote Meeting

Dear Friend of EHDN, On behalf of the members of the Program and Organizing Committee and the Executive Committee of the European Huntington´s Disease Network it is our pleasure to cordially invite you to attend the 3 half-day EHDN Remote Meeting on Thursday – Saturday, September 9-11, 2021. […]

Weiterlesen…

EHDN statement on the discontinuation of the GENERATION HD1 trial

On Monday 22 March 2021 Roche announced that dosing is being permanently discontinued in the GENERATION HD1 phase III trial evaluating the effect of tominersen, an ASO-based huntingtin lowering drug on the clinical course of HD. Dosing is also being paused on the open label extension study, GEN-EXTEND. This decision is the outcome of a […]

Weiterlesen…